# Camrelizumab + rivoceranib

Source: https://onco.cc/drugs/camrelizumab-rivoceranib/  
OnCo record `camrelizumab-rivoceranib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Chinese immunotherapy-plus-anti-angiogenic pill combination that clearly beat sorafenib in liver cancer, yet remains unapproved in the US after three manufacturing-related rejections.

## Summary

CARES-310: median OS 23.8 vs 15.2 months (HR 0.62) and PFS 5.6 vs 3.7 months versus sorafenib in first-line unresectable HCC; approved in China (2023). FDA complete response letters in May 2024, March 2025 and July 2026, each on cGMP inspection deficiencies at the rivoceranib manufacturing site, not on clinical data. Rivoceranib (apatinib) is a selective VEGFR2 TKI; camrelizumab is a PD-1 antibody notable for reactive cutaneous capillary endothelial proliferation, which the TKI suppresses.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-07
- Code: SHR-1210 + apatinib
- Modality: PD-1 antibody + oral VEGFR2 inhibitor
- Mechanism: PD-1 blockade plus VEGFR2 inhibition (vascular normalisation and reduced immunosuppression).
- Approvals: China 2023: First-line unresectable HCC

## Sources

- ClinicalTrials.gov NCT03764293 (CARES-310): https://clinicaltrials.gov/study/NCT03764293

## Connected records

- cancers: [Advanced hepatocellular carcinoma (BCLC C)](https://onco.cc/cancers/hcc-advanced/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [PD-1](https://onco.cc/targets/pd1/), [VEGF / VEGFR](https://onco.cc/targets/vegf/)
- companies: [Elevar Therapeutics (HLB)](https://onco.cc/companies/elevar-therapeutics/), [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)
- trials: [CARES-310](https://onco.cc/trials/cares-310/)
- people: [Shukui Qin](https://onco.cc/people/qin-shukui/)
- drugs: [Rivoceranib (apatinib)](https://onco.cc/drugs/rivoceranib/)

---
JSON: https://onco.cc/api/v1/entities/camrelizumab-rivoceranib.json